secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001104659-25-066724
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma's bivamelagon Phase 2 meets endpoints: -9.3% BMI reduction at 14 weeks
--------------------------------------------------------------------------------

- BMI reduction -9.3% (600mg, p=0.0004) and -7.7% (400mg, p=0.0002) vs 2.2% increase on placebo.
- Mean reduction >2.8 points in 'most' hunger score on 10-point scale in 600mg and 400mg cohorts.
- Safety consistent with MC4R agonism; one discontinuation due to serious AE (rectal bleeding).
- Rhythm plans End-of-Phase 2 meeting with FDA and EU scientific advice for registrational path.
- Data from 26 of 27 patients continued into open-label extension as of July 7, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/0001104659-25-066724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925066724/tm2520203d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-066724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer